Aurinia Pharmaceuticals Gets a Buy from Cantor FitzgeraldBy Ryan Adsit
According to TipRanks.com, Piros is a 1-star analyst with an average return of -3.2% and a 44.6% success rate. Piros covers the Healthcare sector, focusing on stocks such as Dimension Therapeutics Inc, Global Blood Therapeutics, and Bellicum Pharmaceuticals.
Currently, the analyst consensus on Aurinia Pharmaceuticals is Strong Buy and the average price target is $12, representing a 71.4% upside.
In a report issued on April 7, FBR Capital also reiterated a Buy rating on the stock with a $11 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aurinia Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on discovering and developing immunomodulating therapeutics. The company’s pipeline includes voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.